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Safety of Beta-hCG+Erythropoietin in Acute lschemic Stroke. 
Steven C Cramer, Camille Fitzpatrick, Michael Warren, Lawrence Pion, Univ of Calttornia, 
Irvine, Irvine, CA; Laura Whitaker, Hoag Memorial Hosp Presbyterian, Newport Beach, CA; 
Karla Jo Ryckborst, Univ of Calgary, Calgary, Canada; David Brown, Hoag Memorial Hosp 
Presbyterian, Newport Beach, CA; Michael Hill; Univ of Calgary, Calgary, Canada 
Objectives: There are no approved medications to treat stroke beyond the third hour. Studies 
in animals and in humans suggest that erythropoietin might improve outcome when 
administered within a multi-hour time window after stroke onset. Also, addition of a second 
neurotrophic factor might augment erythropoietin effects. The current investigation is a three 
center, single dose, open label, non-controlled, Phase Ila study to assess the safety of beta-hCG 
followed by erythropoietin (B-E therapy) in the treatment of early stroke. Methods: Entry crtteria 
included supratentorial ischemic stroke <48 hours in duration, age 21-85 years, and NIHSS 
6-24. Treatment consisted of a 9-day B-E therapy course, consisting of 3 once-daily IM hCG 
doses on days 1, 3 and 5 followed by a one day washout period (day 6), followed by 3 daily 
IV erythropoietin doses on days 7, 8, and 9. Results: Of the 15 eligible patients enrolled, 2 died, 
neither related to study therapy: one with multiorgan failure plus abdominal hemorrhage from 
heparin for concomitant Ml; and one on day 26 of cardiac arrest in setting of subarachnoid 
hemorrhage. The latter patient also had an arm DVT on day 5, and thus received no 
erythropoietin. One of 13 patients receiving the day 42 leg duplex showed a DVT (in the calf). 
One patient wtth atrial fibrillation had two addttional cerebral emboli prior to erythropoietin, 
received the full B-E therapy course, and did well (day 90 NIHSS=3). Of patients assessed 
through day 90, NIHSS score improved from baseline 9 ±4 to 3 ±2 (mean±SD), Barthel at 
day 90 was < =95 in 8/12, and significant domain-specific gains were measured in motor, 
language, and attention. Serum hemoglobin did not increase significantly across any of the five 
assessments over 42 days, though reticulocyte count did. The day 90 infarct volume (n = 7) was 
22±34% lower than at baseline. Conclusions: A 9 day course of beta-hCG+Erythropoietin 
started within 48 hours of stroke onset is safe, had minimal hematological effects, and was 
associated with signtticant clinical gains. A randomized, placebo-controlled trial of B-E therapy 
in patients with stroke is therefore appropriate, and has been initiated. CLINICALTRIALS.GOV 
IDENTIFIER: NCT00362414. 
